Dr. Murray Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative); F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto; Professor in the Faculties of Medicine and Pharmacy, University of Toronto; Senior Scientist at the Toronto General Hospital Research Institute; and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. He completed a Master's Degree in Clinical Epidemiology at McMaster University, and a Clinical Fellowship in Medical Decision Making at the New England Medical Centre in Boston. Dr. Krahn's research program focuses on the use of decision analytic methods to examine health policy and health decision-making. He leads one of the leading technology assessment institutes in the country.
My central area of research interest has been the application of decision analysis and economic evaluation to broad questions of health and clinical policy. This methodologic focus has been expressed in a variety of content areas including prostate cancer and viral hepatitis. More recent interests include evaluating the role of disease specific utility assessment, using administrative data to build longitudinal cost models, and evaluating the role of health technology assessment in pharmaceutical reimbursement decisions.
Pharmacotherapy versus surgery as initial therapy for patients with moderate-to-severe benign prostate hyperplasia: a cost-effectiveness analysis.
BJU Int. 2018 Aug 16;:
Resource Utilization and Costs in Adolescents Treated for Cancer in Pediatric vs Adult Institutions.
J Natl Cancer Inst. 2018 Jul 19;:
DEVELOPMENT OF THE ONTARIO DECISION FRAMEWORK: A VALUES BASED FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT.
Int J Technol Assess Health Care. 2018 Jan;34(3):290-299
Cost analysis of Greenlight photoselective vaporization of the prostate compared to transurethral resection of the prostate for benign prostatic hyperplasia.
Can Urol Assoc J. 2018 Jun 19;:
The lifetime cost of spinal cord injury in Ontario, Canada: A population-based study from the perspective of the public health care payer.
J Spinal Cord Med. 2018 Jun 20;:1-10
Nucleic Acids Res. 2018 May 31;:
Carpal Tunnel Syndrome Management in Breast Cancer Survivors at Risk for Lymphedema: A Markov Model.
Plast Reconstr Surg. 2018 May;141(5):689e-696e
MPA, a Free, Accessible, and Efficient Pipeline for Single Nucleotide Variant Annotation and Prioritization for Next-Generation Sequencing Routine Molecular Diagnosis.
J Mol Diagn. 2018 Apr 21;:
J Am Geriatr Soc. 2018 Apr 20;:
J Wound Care. 2017 07 01;26(Sup7):S4-S13
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Director of THETA (Toronto Health Economics and Technology Assessment Collaborative)
F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto
Professor in the Faculties of Medicine and Pharmacy, University of Toronto
Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto.